About Vencarm XL

Welcome to

Vencarm XL is a prolonged-release capsule of venlafaxine indicated for the:1

  • Treatment of major depressive episodes

  • Prevention of recurrence of major depressive episodes

  • Treatment of generalised anxiety disorder

  • Treatment of social anxiety disorder

  • Treatment of panic disorder, with or without agoraphobia

Available as:

  • 37.5mg prolonged-release capsules

  • 75mg prolonged-release capsules

  • 150mg prolonged-release capsules

  • 225mg prolonged-release capsules

Vencarm XL is bioequivalent to the originator EFEXOR XL (venlafaxine prolonged-release capsules) (Pfizer Ltd) based on biostudies using TREVILOR® retard (Venlafaxine Hydrochloride Prolonged-release) Capsules, (Pfizer Pharma GmbH, Germany)2

  • jhbcxhqbchqwbichqbwichb

Vencarm XL could offer significant cost savings to your practice and clinical commissioning group (CCG).

venlafaxine 37.5mg, 75mg, 150mg and 225mg prolonged-release capsules are in category C of the UK Drug Tariff.3

However, the NHS could make up to 79% savings on the cost of category C venlafaxine by prescribing Vencarm XL by brand name.3*

Vencarm XL is one of Aspire Pharma’s cost saving prolonged-release products.

Quite simply a wholesale switch of venlafaxine prolonged-release 37.5mg, 75mg, 150mg and 225mg tablet and capsule prescriptions to Vencarm XL could save an average CCG £35,167 per year.4***

In addition:

  • Full range of strengths available for Vencarm XL;

  • Available from mainline wholesalers;

  • High level of stockholdings;

  • Bioequivalent to the originator brand;2

  • Price guaranteed**

*Based on up to 79% saving on the cost of Category C venlafaxine XL capsules and tablets in the UK Drug Tariff. **No change in price subject to no material change to the products or Category C of the UK Drug Tariff until the 2024 PPRS review. ***Savings based on market data in reference 4. Savings calculated from 2018 spend for 217 CCGs switching their generic and originator brand 37.5mg, 75mg, 150mg and 225mg venlafaxine prolonged-release tablets and capsules prescriptions to Vencarm XL.
References 1) Vencarm XL SmPCs. 2) Data on file. 1010344221 v 2.0 September 2019. 3) March 2020 UK Drug Tariff. 4) ePact data Jan-Dec 2018


For further information please call: 01730 231148,
email: or visit
Adverse events should be reported. Reporting forms and information can be found at
Adverse events should also be reported to Aspire Pharma Ltd on 01730 231148

For more information about Vencarm XL (venlafaxine), please see the abbreviated prescribing information.

Revision reference – Vencarm XL_7_09.12.2020

More products available
in this range:
Click to view their
individual websites